CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interaction between TIM-3 and its four ligands (galectin 9, high mobility group protein B1, phosphatidyl serine, and carcinoembryonic antigen cell adhesion molecule 1) can diminish anti-tumor immunity through a variety of mechanisms including inducing CD8+ T cell death and exhaustion (Huang et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Huang et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We stimulated primary microglia with galectin-9 and CEACAM1, both of which mediate TIM-3 function in T cells by phosphorylating Y256 and Y263 residues34,35. This treatment had no effect on pSMAD2 expression”
From Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · cited 2×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 4×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
InfluentialHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Multiple Sequence Alignment Using ClustalW and ClustalX
Thompson, J. D., Gibson, T. J., & Higgins, D. G. (2003) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi0203s00 · Cited by 2,971 · cited 1×
“In addition, multiple sequencealignmentswereperformedusingClustalW 45 .”
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860 · cited 2×
“ThedatawereprocessedwithMosflm 40 andthe CCP 4softwaresuite 41 .”
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419
Cited by
Items 601–700 of 718
Regulation of mast cell function by TIM-1 and TIM-3 signaling
Phong, B. L. (2016) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 2
Editorial: Countering immune regulation: sTim-ulating SLE disease pathogenesis
Clayton, K., & Ostrowski, M. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ce0717-279rr · Cited by 1
“In addition to PS and galectin-9, sTim-3 may interact with CEACAM1, a coinhibitory molecule that binds to Tim-3 to induce coinhibitory function [9].”
BackgroundSelf-citationThe co-stimulatory activity of Tim-3 requires Akt and MAPK signaling and immune synapse recruitmentPreprint
Kataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.30.878520 · Cited by 1
“As suggested by others, interactions of Tim-3 in trans with other transmembrane proteins like CEACAM1 (42) or phosphatases (34) could modulate the signaling function of Tim-3 toward an inhibitory pathway.”
BackgroundInfluentialCong, Y., Cui, Y., Zhu, S., Cao, J., Qiao, G., Zou, H., Jiang, W. G., & Yu, Z. (2020) · doi:10.21203/rs.2.22315/v2 · Cited by 1
Editorial: Checkpoint inhibition in hematologic malignancies
Pu, J. J., Drabick, J. J., & Prockop, S. E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429854 · Cited by 1
Tim-3 Promotes Early Differentiation of Tbet + Effector T Cells During Acute Viral InfectionPreprint
Manandhar, P., Landy, E., Mori, K., & Kane, L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.08.663709 · Cited by 2
“Multiple ligands for Tim-3 have been discovered, which have been reported to function as both positive and negative regulators of Tim-3, in different contexts (Dardalhon et al., 2010; Huang, 2015; Smith et al., 2021; Wolf et al., 2020).”
A Subset Apart? Th9 cell regulation and current limitations to study
Zheng, Z., & Kang, J. (2015) · Journal of nature and science
Novel Immunomodulatory Pathways in the Immunoglobulin Superfamily
Rennert, P. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-29827-6_2
Immunothérapie : les checkpoints
Caux, C. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30128-8
Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
Fountzilas, C. K., Lee, S. S., Iyer, R. V., & Boland, P. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00004-4
[Tole of T cell exhaustion in inducing immune tolerance and preventing graft-versus-host disease].
Wang, J., & Han, M. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.02.015
Role of Immune Inhibitors in Ovarian Cancer
Lu, H., Gu, F., & Wang, F. (2019)
Cancer Immunotherapy: Beyond Checkpoint Inhibitors
Hasan, M. R., Alotaibi, B. S., Alnomasy, S. F., & Fakhri, K. U. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-6530-8.ch001
Antibody‐Based Therapeutics in Oncology
Moore, P. A., Motte-Mohs, R. N. L., Li, J. C., & Chichili, G. R. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch16
Mohammed, A. S., Daoud, S. A., Moustafa, W. I., Sayed, O., Ibrahim, B. B., Sayed, M. M., & Mohammed, S. A. (2021) · Egyptian Journal of Medical Research · doi:10.21608/ejmr.2021.175726
“As mentioned before, CEACAM-1 serves as a heterophilic ligand for TIM-3 which is required for its ability to mediate T-cell exhaustion, and this interaction is crucial in regulating anti-tumor immunity (7).”
BackgroundPerspectives of Radiotherapy in Immuno-oncology Era
Hsu, Y. C.-F., & Cheng, J. C. (2021) · Springer eBooks · doi:10.1007/978-981-16-1815-4_23
Wu, W., Zhang, Y., Wang, Y., Liu, P., Sun, S., Hong, M., Yuan, Y., Xia, Q., & Chen, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-670384/v1
Characterizing the Development of T cell Exhaustion Independent of PD-1
Freeman, Z. T. (2016)
Immunology and immunotherapy in CRC
Cordero, O. J., Varela‐Calviño, R., Graña-Suárez, B., & García-López, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00031-4
Restoration of hemopoiesis in patients following chronic radiation sickness
Gribova, I. A., & Soldatva, V. A. (1975) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Immunology and Immunotherapy of Colorectal Cancer
Cordero, O. J., Varela‐Calviño, R., & Graña-Suárez, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_10
Garg, S., Kumar, S., Anand, A., Menon, T., Sharma, N., Singh, J., Chawla, S., & Das, A. (2022) · Vegetos · doi:10.1007/s42535-021-00329-4
Zhang, X., Wang, M., Lu, H.-Q., He, Q., You, Y., Zhou, X., Fu, X., Liang, D., Kwan, H. Y., Zhao, X., et al. (2020) · doi:10.21203/rs.3.rs-27520/v1
Cong, Y., Cui, Y., Zhu, S., Cao, J., Qiao, G., Zou, H., Jiang, W. G., & Yu, Z. (2020) · doi:10.21203/rs.2.22315/v1
“Accumulating evidence demonstrate that Tim-3 can reduce cell proliferation, decrease the production of effective cytokines and increase apoptosis of effector T cells, through interaction with its ligands including galectin-9, high mobility group protein B1 (HMGB1), carcinoembryonic antigen related cell adhesion molecu…”
BackgroundKane, L. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726868692.793543536
Regulatory T Cells - New Insights
He, X. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.98075
Triviño, J. Y. M. (2020) · Repositorio Institucional (Pontificia Universidad Javeriana) · doi:10.11144/javeriana.10554.49675
Morozova, E. V., Tsvetkov, N., Barabanshchikova, M. V., Yurovskaya, K., & Moiseev, I. (2022) · Oncohematology · doi:10.17650/1818-8346-2022-17-4-106-117
Datta, R. R., Schran, S., Persa, O., Aguilar, C., Thelen, M., Lehmann, J. M., Garcia-Marquez, M. A., Wennhold, K., Preugszat, E., Zentis, P., et al. (2023) · doi:10.1158/1078-0432.c.6532569.v1
Walwyn-Brown, K., Pugh, J. L., Cocker, A. T. H., Beyzaie, N., Singer, B. B., Olive, D., Guethlein, L. A., Parham, P., & Djaoud, Z. (2023) · doi:10.1158/2326-6066.c.6550517
Eskiocak, B., McMillan, E. A., Mendiratta, S., Kollipara, R. K., Zhang, H., Humphries, C. G., Wang, C., García‐Rodríguez, J., Ding, M. L., Zaman, A., et al. (2023) · doi:10.1158/2159-8290.22531915
Eskiocak, B., McMillan, E. A., Mendiratta, S., Kollipara, R. K., Zhang, H., Humphries, C. G., Wang, C., Garcia-Rodriguez, J., Ding, M. L., Zaman, A., et al. (2023) · doi:10.1158/2159-8290.22531915.v1
Local Onco-Sphere: Tumor–Immune Cells Interactions
Saw, P. E., & Song, E. (2023) · Springer eBooks · doi:10.1007/978-981-99-1183-7_3
Berzofsky, J. A., Olkhanud, P. B., & Maeng, H. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00014-1
Post-transplant inflammatory bowel disease associated with donor-derived TIM-3 deficiencyPreprint
Baldrich, A., Althaus, D., Menter, T., Hirsiger, J. R., Köppen, J., Hupfer, R., Bosch, A. J. T., Drexler, B., Gerull, S., Ghosh, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3282819/v1
Studstill, C. J. (2020) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/88918
Chen, D., He, Y., Feng, Z., Dong, L., & Yang, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3829624/v1
Shan, X., Renauer, P. A., Dong, C., Feng, Y., Ren, P., Lin, Q., Zhang, F., Tafreshi, N., Glazer, P. M., Chen, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.14.575614
Influence of SLC40A1 on Cytokine Interaction and Immune Infiltration in GlioblastomaPreprint
Jiang, J., Duan, R., Zhu, J., Yan, J., Ye, J., & Luo, C. (2024) · Research Square · doi:10.21203/rs.3.rs-3872535/v1
Other Immune Checkpoint Targets of Interest
Csizmar, C. M., & Ansell, S. M. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch12
Chen, Z., Su, J., You, N., Lin, H. L., Lin, S., Zhang, Z., & Chen, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29387
“In a mouse model of colorectal cancer, blocking HAVCR2 increased anti-tumor responses and promoted tumor clearance [45].”
WITHDRAWN: Next generation immune checkpoints
Perez, N. M., Moziak, K., & Martin, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00009-6
Kong, H., Wu, X., Yang, Q., Sun, Q., Yu, X., Dai, Y., Wu, C.-W. G., Xie, D., Chen, L., Ma, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.24.604770
Marvelon suppresses MC38 tumor growth and promotes anti-tumor immunity
Kong, F., Chen, Y., Liu, D., Gao, H., Yi, Q., Zhang, M., & Li, D. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.03.011
The molecules with double-edged sword roles in T cell: An implication for adoptive T cell therapy
Samiee, M., Salehi, S., Khosroshahi, L. M., & Soltantoyeh, T. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104810
Investigation of a Stable Interaction of Levothyroxine with AFP Through Molecular Modelling
Akbaba, E., Karataş, D., Gönel, A., Soylu, E., Kiraz, B., & Almahdi, Y. A. (2025) · Cumhuriyet Science Journal · doi:10.17776/csj.1599148
Smith-Oliver, M. R., Gautam, D., Clarke, E. M., Petrarca, G. C., Sullivan, M. E., Goggi, G., Spasić, M. R., Kane, N., Roweth, H. G., Garrido-Castro, A. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675650
Azimi, F., Khakpour, G., Sedaghat, A., Mostafaiee, F., Mirshahi, R., & Naseripour, M. (2024) · Journal of Current Ophthalmology · doi:10.4103/joco.joco_145_24
Cheng, B., Tibbe, T. D., Yao, S., Wei, M., Wong, Z. Y., Torgerson, T., Chiu, R., Kasargod, A., Nakamura, K., Cappelletti, M., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.194227
“Specifically, Ceacam1-deficient donor livers may lack the ability to interact in trans with CEACAM1 and T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) expressed on recipient T cells — ligands known to modulate favorable immune responses to inflammation and tissue injury (12).”
Allela, O. Q. B., Shareef, A., Bishoyi, A. K., Oweis, R. J., Ballal, S., Singh, A., Sinha, A., Ray, S., Sameer, H. N., Yaseen, A., et al. (2025) · Immunological Investigations · doi:10.1080/08820139.2025.2571960 · Cited by 2
TIM-4 Regulates Allergic Airway Inflammation and Mast Cell Activation by Binding to CD300b
Tanabe, Y., Kamachi, F., Ito, J., Harada, N., Harada, S., Makino, F., Abe, Y., Nakano, N., Izawa, K., Niyonsaba, F., et al. (2025) · Journal of Asthma and Allergy · doi:10.2147/jaa.s550326
Huang, J., Zhou, L., & Deng, K. (2023) · Figshare · doi:10.6084/m9.figshare.22626293
Ding, P., Du, Y., Jiang, X., Chen, H., & Huang, L. (2024) · Figshare · doi:10.6084/m9.figshare.26669580
Qiu, H., Shao, Z., Wen, X., Qu, D., Liu, Z., Chen, Z., Zhang, X., Ding, X., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.26402033
Qiu, H., Shao, Z., Wen, X., Qu, D., Liu, Z., Chen, Z., Zhang, X., Ding, X., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.26401837
戴五敏, Feng, J., Hu, X., Chen, Y., Gu, Q., Gong, W., Feng, T., & Wu, J. (2021) · Figshare · doi:10.6084/m9.figshare.14121842
戴五敏, Feng, J., Hu, X., Chen, Y., Gu, Q., Gong, W., Feng, T., & Wu, J. (2021) · Figshare · doi:10.6084/m9.figshare.14121839
Qiu, H., Shao, Z., Wen, X., Qu, D., Liu, Z., Chen, Z., Zhang, X., Ding, X., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.26755405
Huang, J., Zhou, L., & Deng, K. (2023) · Figshare · doi:10.6084/m9.figshare.22626290
Huang, J., Zhou, L., & Deng, K. (2023) · Figshare · doi:10.6084/m9.figshare.22626296
Huang, J., Zhou, L., & Deng, K. (2023) · Figshare · doi:10.6084/m9.figshare.22626302
戴五敏, Feng, J., Hu, X., Chen, Y., Gu, Q., Gong, W., Feng, T., & Wu, J. (2021) · Figshare · doi:10.6084/m9.figshare.14121848
Ding, P., Du, Y., Jiang, X., Chen, H., & Huang, L. (2024) · Figshare · doi:10.6084/m9.figshare.25034493
Ding, P., Du, Y., Jiang, X., Chen, H., & Huang, L. (2024) · Figshare · doi:10.6084/m9.figshare.25034430
Huang, J., Zhou, L., & Deng, K. (2023) · Figshare · doi:10.6084/m9.figshare.22626287
Huang, J., Zhou, L., & Deng, K. (2023) · Figshare · doi:10.6084/m9.figshare.22626299
Qiu, H., Shao, Z., Wen, X., Qu, D., Liu, Z., Chen, Z., Zhang, X., Ding, X., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.26755402
Dolui, B., Majumdar, B., Bandyopadhyay, A., Desai, K. V., & BASU, A. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111096 · Cited by 1
“…cell proliferation, diminished cytokine production, and increased apoptosis of effector T cells through interactions with its ligands, including galectin-9, high mobility group protein B1 (HMGB1), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1), and phosphatidylserine (11, 12).”
Huang, F., Li, H., Miu, T., Chen, X., Wang, Y., Wang, Z., Zou, S., 覃理灵, & Zhi, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109417 · Cited by 3
Mechanisms and strategies for reversing NK cell exhaustion in tumor immunotherapy
Zhi, L., Wang, Y., Zhao, Z., Guo, Y., Wang, K., He, W., Guo, C., Niu, Z., Zhu, W., & Zhang, X. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105031 · Cited by 1
Integrative Omics Analysis Reveals the Potential Value of CEACAM6 in Pan‐Gastrointestinal Cancers
Jin, L., Tao, C., Pan, Z., & Zhang, P. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70327
CT26.MtC3, a new preclinical model to investigate immune resistance in metastatic colorectal cancer
Bienassis, C., SILVA, J. D., Fournil, N., Prezado, Y., Mégnin-Chanet, F., & Paris, S. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04200-x
“Mechanistically, CEACAM-1 supports epithelial-to-mesenchymal transition (EMT), tumor cell intravasation, and resistance to T-cell–mediated killing [45, 51].”
Bibliometric analysis of knowledge maps and future trends of TIM-3 in cancer
Lv, S., Huang, S., Li, L., Lin, K. L., Zhang, H. Q., & Huang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1766463
Self-citationChen, J., Zhang, L., Luo, Y., Han, X., Kang, M., Chen, J., Liu, W., Xun, Z., Chen, G., Chen, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.05.708917
Inhibitory receptor agonists: Emerging strategies in immune modulation
Adam, K. R., Suhail, A., Kuchroo, V. K., & Vignali, D. A. A. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20241217 · Cited by 1
Self-citationTranslating IL-2/anti-IL-2 antibody complexes treatment for human tumor immunotherapy
Caudana, P. (2018) · theses.fr (ABES) · doi:10.70675/8a93b17bz416az4e49z9a3bz92c1c8a4cf8c
Vinot, P.-A. (2018) · theses.fr (ABES) · doi:10.70675/8d700747z53d5z4ad2z91fbz840e35448ca7
Rôle de la Neuropiline-1 dans les fonctions effectrices des lymphocytes T CD8 antitumoraux
Leclerc, M. (2018) · theses.fr (ABES) · doi:10.70675/13aee211zad7bz4b07z9a5fz29b15750d99c
TIM-3 in Cardiovascular Disease
Yousif, L. I. E., Sijtema, A. G., Chevalier, M. J., de Boer, R. A., & Meijers, W. C. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00755-y
“CEACAM1 has been associated with TIM-3 in cis during early biosynthesis, enabling surface expression and stability on T cells, while trans binding permitted TIM-3 inhibitory activity in T cells by releasing BAT3 [40].”
Efficacy and synergy of low-dose radiotherapy combined with anti-PD-L1 based immunotherapy
Laurent, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/e7695737z26a3z4747zafafzb19e3e74372b
Immune Checkpoint Molecules: Structure, Function, and Expression
Tayebi, L., & Abdolmaleki, M. (2026) · Springer eBooks · doi:10.1007/978-981-95-8026-2_2
Liu, K., Liu, S., Wang, D., Han, T., Qiao, H., & Fang, Q. (2026) · Scientific Reports · doi:10.1038/s41598-026-50008-0 · Cited by 1
Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies
Ge, Q., Yu, L., Lu, J., Anwaier, A., Xiao, X., Chen, Y., Ye, D., Zhang, H., Xu, W., & Dai, W. (2026) · MedComm · doi:10.1002/mco2.70771 · Cited by 1
Translational Gap in Biomarker Discovery: Tumor Surface Markers Rarely Mirror Circulating Levels
Mukohyama, J., Fujita, S., Fu, X., Suzuki, S., Hamamoto, H., Shida, D., Yamashita, K., Taniguchi, K., Lee, S.-W., & Yoshimi, A. (2026) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.70240
“In addition, CEACAM1 has been implicated in TIM-3–mediated immune tolerance and exhaustion, and TIM-3/CEACAM1 co-expression has been associated with T-cell exhaustion in patients with CRC [21, 22].”
Tevetoğlu, F., Çomunoğlu, N., & Yener, M. (2026) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.70453
Kim, K. H., Lee, D. Y., Yang, H. J., Kim, S. H., Kim, D. S., Lee, C. H., Hong, S. A., Chi, B. H., Lee, J. G., & Jeon, Y. S. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101278 · Cited by 3
Gao, S., Li, Z., Zhang, R., Zhu, X., Cheng, Y., Zhao, M., & Xu, Y. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105440
Zhang, W., Yuan, W., Yuan, C., Cheng, Y., Zhang, D., Cao, X., & Ding, C. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.06.004
CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma
Sethapati, V. R., Ngo, V. N., Danilov, A., Phillips, T. J., Shouse, G., Herrera, A., Perry, A. M., Li, A., Kwak, L. W., Weisenburger, D. D., et al. (2026) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqag078
Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy
Banerjee, H., Onyekachi, O. V., Nieves-Rosado, H. M., Murter, B., Kulkarni, A., Pandey, S., Cardona, E., Dougherty, J. E., Li, H., Upadhyay, P., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0687
Metadata
- Authors
- Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., Clayton, K. L., Raab, M., Chen, Q., Beauchemin, N., Yazaki, P. J., Pyzik, M., Ostrowski, M. A., Glickman, J. N., Rudd, C. E., Ploegh, H. L., Franke, A., Petsko, G. A., Kuchroo, V. K., & Blumberg, R. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Brandeis University (US)
- Massachusetts Institute of Technology (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Oslo University Hospital (NO)
- University of Toronto (CA)
- University of Cambridge (GB)
- Sichuan University (CN)
- McGill University (CA)
- City Of Hope National Medical Center (US)
- St. Michael's Hospital (CA)
- Corresponding author
- Blumberg, Richard S.
- ORCID
- Venue
- Nature
- Published
- 2014-10-26
- Volume
- 517
- Issue
- 7534
- Pages
- 386-390
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4297519
- OpenAlex
- W2122730216
- Cited by
- 717
- References
- 58
- Citations by year
- 2026: 44 · 2025: 72 · 2024: 85 · 2023: 82 · 2022: 71 · 2021: 82 · 2020: 76 · 2019: 51 · 2018: 47 · 2017: 40 · 2016: 38 · 2015: 28
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001102)
- National Institute of General Medical Sciences (R01GM032415, T32GM007122, GM-32415, R37GM032415, P41GM111244, R01GM026788)
- National Institute of Allergy and Infectious Diseases (AI 056299, P01AI073748, AI039671, AI073748, P01AI056299, P01AI039671)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK044319, DK0034854, R01DK053056, DK088199, DK053056, R56DK053056, DK051362, R37DK044319, R01DK051362, P30DK034854, R01DK044319, R01DK088199)
- National Institute of Neurological Disorders and Stroke (NS045937, R01NS045937)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TIM-3, T cell exhaustion, immune tolerance, immune checkpoint, T cell co-inhibition, T cell costimulation, colorectal cancer, antitumor immunity, T cell receptor signaling
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Cell Line, Disease Models, Animal, Female, Humans, Immune Tolerance, Inflammation, Ligands, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Molecular, Mucous Membrane, Protein Conformation, Receptors, Virus, T-Lymphocytes, Colorectal Neoplasms, Autoimmunity, Antigens, CD, Cell Adhesion Molecules, Mice, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.